{
    "clinical_study": {
        "@rank": "124313", 
        "arm_group": [
            {
                "arm_group_label": "Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine", 
                "arm_group_type": "Experimental", 
                "description": "use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection"
            }, 
            {
                "arm_group_label": "Live Attenuated Varicella Vaccine", 
                "arm_group_type": "Experimental", 
                "description": "use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection"
            }, 
            {
                "arm_group_label": "Live Attenuated JE Vaccine", 
                "arm_group_type": "Experimental", 
                "description": "use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the occurrence of adverse events and seroconversion\n      rate, geometric mean titres (GMTs) of live attenuated varicella vaccine\uff0clive attenuated JE\n      vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine,\n      respectively."
        }, 
        "brief_title": "Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Japanese Encephalitis", 
            "Chickenpox"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Chickenpox", 
                "Encephalitis", 
                "Encephalitis, Japanese"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parent/legal acceptable representative is willing and able to understand the protocol\n             requirements and provide informed consent\n\n          -  Participant is aged \u2265 1 year to \u2264 3 years\n\n          -  Participant without previous history of chickenpox, zoster and epidemic encephalitis\n             B\n\n          -  Subject and parent/guardian able to attend all scheduled visits and comply with all\n             trial procedures\n\n          -  Body temperature \u2264 37.5\u2103\n\n        Exclusion Criteria:\n\n          -  Known allergy to any constituent of the vaccine\n\n          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease\n             and fever\n\n          -  Known or suspected impairment of immunologic function, or receipt of\n             immunosuppressive therapy or immunoglobulin since birth\n\n          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain\n             disease and clear serious systemic reaction\n\n          -  Failed to the Expanded Programme on Immunization(EPI)\n\n          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination\n\n          -  Plan to receive any vaccine in the 4 weeks following the trial vaccination\n\n          -  Known bleeding disorder\n\n          -  Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the\n             trial vaccination\n\n          -  Reported the history of acute illness had need systemic antibiotics or anti-viral\n             treatment of infections in the 7 days preceding the trial vaccination\n\n          -  An acute illness with or without fever (temperature \u2265 38.0\u2103) in the 3 days preceding\n             enrollment in the trial\n\n          -  Participation in any other interventional clinical trial\n\n          -  Any condition which, in the opinion of the investigator, would pose a health risk to\n             the subject or interfere with the vaccine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "3 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "497", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815073", 
            "org_study_id": "NCT02049715"
        }, 
        "intervention": [
            {
                "arm_group_label": "Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine", 
                "intervention_name": "Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Live Attenuated Varicella Vaccine", 
                "intervention_name": "Live Attenuated Varicella Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Live Attenuated JE Vaccine", 
                "intervention_name": "live attenuated JE vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong"
                }, 
                "name": "Guangzhou Haizhu District Center for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine", 
        "overall_official": {
            "affiliation": "Guangdong Center for Disease Control and Prevention", 
            "last_name": "Zheng Huizhen, Master", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Seroconversion rate and GMTs for live attenuated varicella vaccine, live attenuated JE vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine, respectively.", 
            "safety_issue": "No", 
            "time_frame": "35-42 days after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Occurrence of adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days after each vaccination"
        }, 
        "source": "Changchun Keygen Biological Products Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangdong Provincial Institute of Biological Products And Materia Medica", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Changchun Keygen Biological Products Co., Ltd.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}